Menopausal hormone therapy + bisphosphonates

1. Menopausal hormone therapy + bisphosphonates increase femoral neck bone mineral density in humans (MD 4.87%; 95% CI 2.66–7.07).

   “MHT plus bisphosphonate therapy showed the most favorable BMD profile, including at the femoral neck (MD, 4.87%; 95% CI, 2.66-7.07)”

   Reviewpostmenopausal women; compared with controlfemoral neckfemales

   Menopausal hormone therapy combined with antiresorptive therapy for skeletal outcomes in postmenopausal women: a systematic review and network meta-analysis of randomized controlled trials

   Menopause (New York, N.Y.)·13 Oct 2026

More on Femoral neck bone mineral density

1. Menopausal hormone therapy + bisphosphonates increase lumbar spine bone mineral density in humans (MD 9.71%; 95% CI 6.99–12.42).

   “MHT plus bisphosphonate therapy (MD, 9.71%; 95% CI, 6.99-12.42)”

   Reviewpostmenopausal women; compared with controllumbar spinefemales

   Menopausal hormone therapy combined with antiresorptive therapy for skeletal outcomes in postmenopausal women: a systematic review and network meta-analysis of randomized controlled trials

   Menopause (New York, N.Y.)·13 Oct 2026

More on Lumbar spine bone mineral density

1. Menopausal hormone therapy + bisphosphonates lower the risk of fractures in humans (RR 0.51; 95% CI 0.28–0.93).

   “MHT plus bisphosphonate therapy was associated with a lower risk of any fracture compared with control (risk ratio, 0.51; 95% CI, 0.28-0.93)”

   Reviewpostmenopausal women; compared with control; sparse fracture events, often not prespecified efficacy outcomesfemales

   Menopausal hormone therapy combined with antiresorptive therapy for skeletal outcomes in postmenopausal women: a systematic review and network meta-analysis of randomized controlled trials

   Menopause (New York, N.Y.)·13 Oct 2026

More on Fractures